// App-Quantinova.ai

e22105 : A pilot feasibility study to evaluate the efficacy of lapatinib in eliminating HER2-positive tumor cells circulating in peripheral blood of women with metastatic breast cancer.

Researchers

Presenter

  • Sofia Agelaki

Principal Investigators

  • Antonia Kalykaki

  • Haris Markomanolaki

  • Galatea Kallergi

  • Kostas Kalbakis

  • Dimitrios Mavroudis

  • Vassilis Georgoulias

Medical Centers

  • University General Hospital of Heraklion, Department of Medical Oncology, Heraklion, Greece

  • Laboratory of Tumor Cell Biology, School of Medicine, University of Crete, Heraklion, Greece

Locations

  • Greece

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Peripheral blood mononuclear cell

  • Circulating tumor cells

  • Epidermal growth factor receptor

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Lapatinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT00694252

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved